These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 35125081)

  • 1. An Insight into the Molecular Mechanism of Mitochondrial Toxicant-induced Neuronal Apoptosis in Parkinson's Disease.
    Brahadeeswaran S; Lateef M; Calivarathan L
    Curr Mol Med; 2023; 23(1):63-75. PubMed ID: 35125081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial Toxicant-Induced Neuronal Apoptosis in Parkinson's Disease: What We Know so Far.
    Sivagurunathan N; Gnanasekaran P; Calivarathan L
    Degener Neurol Neuromuscul Dis; 2023; 13():1-13. PubMed ID: 36726995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
    Büeler H
    Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial dysfunction and oxidative stress in Parkinson's disease.
    Subramaniam SR; Chesselet MF
    Prog Neurobiol; 2013; 106-107():17-32. PubMed ID: 23643800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease].
    Hattori N
    Rinsho Shinkeigaku; 2004; 44(4-5):241-62. PubMed ID: 15287506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis.
    Banerjee R; Starkov AA; Beal MF; Thomas B
    Biochim Biophys Acta; 2009 Jul; 1792(7):651-63. PubMed ID: 19059336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
    Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
    Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of fibroblasts as a valuable strategy for studying mitochondrial impairment in neurological disorders.
    Olesen MA; Villavicencio-Tejo F; Quintanilla RA
    Transl Neurodegener; 2022 Jul; 11(1):36. PubMed ID: 35787292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
    Zuo L; Motherwell MS
    Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial dysfunctions in Parkinson's disease.
    Gautier CA; Corti O; Brice A
    Rev Neurol (Paris); 2014 May; 170(5):339-43. PubMed ID: 24119854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current perspective of mitochondrial biology in Parkinson's disease.
    Ammal Kaidery N; Thomas B
    Neurochem Int; 2018 Jul; 117():91-113. PubMed ID: 29550604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease.
    Ebadi M; Govitrapong P; Sharma S; Muralikrishnan D; Shavali S; Pellett L; Schafer R; Albano C; Eken J
    Biol Signals Recept; 2001; 10(3-4):224-53. PubMed ID: 11351130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.
    Yue X; Hariri DJ; Caballero B; Zhang S; Bartlett MJ; Kaut O; Mount DW; Wüllner U; Sherman SJ; Falk T
    Neuroscience; 2014 Jan; 258():385-400. PubMed ID: 24291725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuronal complex I deficiency occurs throughout the Parkinson's disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage.
    Flønes IH; Fernandez-Vizarra E; Lykouri M; Brakedal B; Skeie GO; Miletic H; Lilleng PK; Alves G; Tysnes OB; Haugarvoll K; Dölle C; Zeviani M; Tzoulis C
    Acta Neuropathol; 2018 Mar; 135(3):409-425. PubMed ID: 29270838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers in Parkinson's disease (recent update).
    Sharma S; Moon CS; Khogali A; Haidous A; Chabenne A; Ojo C; Jelebinkov M; Kurdi Y; Ebadi M
    Neurochem Int; 2013 Sep; 63(3):201-29. PubMed ID: 23791710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH2 deficiency promotes mitochondrial dysfunction and dopaminergic neurotoxicity: implications for Parkinson's disease.
    Kim H; Kim SH; Cha H; Kim SR; Lee JH; Park JW
    Free Radic Res; 2016 Aug; 50(8):853-60. PubMed ID: 27142242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial pathobiology in Parkinson's disease and amyotrophic lateral sclerosis.
    Martin LJ
    J Alzheimers Dis; 2010; 20 Suppl 2():S335-56. PubMed ID: 20413846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
    Harrison IF; Dexter DT
    Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.